Showing results (331-340 of 366) with videos related to

Sort By:
Pageof 37
Plos One|February 4, 2017
Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assayJiuping Ji, Yiping Zhang, Christophe E Redon, et al.
Stem Cells (Dayton, Ohio)|March 26, 2005
The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engraftmentRossella Manfredini, Roberta Zini, Simona Salati, et al.
Therapeutic Advances in Drug Safety|April 29, 2026
The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patientsStefania Crucitta, Paola Cinacchi, Irene Bargagna, et al.
European Journal of Medicinal Chemistry|May 4, 2015
New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activityClementina Manera, Anna Maria Malfitano, Teija Parkkari, et al.
Breast Cancer Research and Treatment|July 27, 2019
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patientsMarzia Del Re, Ilaria Bertolini, Stefania Crucitta, et al.
Blood|October 27, 2009
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinibRoberto M Lemoli, Valentina Salvestrini, Elisa Bianchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 23, 2013
T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophiliaLaura K Fogli, Mark S Sundrud, Swati Goel, et al.
Breast (Edinburgh, Scotland)|October 25, 2022
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclibMarzia Del Re, Stefania Crucitta, Claudia Omarini, et al.
Clinical Genitourinary Cancer|July 19, 2024
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal CancerMarzia Del Re, Stefania Crucitta, Nicole Brighi, et al.
Critical Reviews in Oncology/Hematology|October 3, 2022
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paperAntongiulio Faggiano, Rossella Mazzilli, Annalisa Natalicchio, et al.
Pageof 37